Atorvastatin influence on cardiac function and rhythm variability in patients with chronic lymphocytic leukemia in remission
DOI:
https://doi.org/10.14739/2409-2932.2019.1.159131Keywords:
chronic lymphocytic leukemia, cardiovascular events, cardiac arrhythmiaAbstract
Purpose – to evaluate atorvastatin influence on cardiac hemodynamics and rhythm variability in patients with chronic lymphocytic leukemia (CLL) in remission.
Materials and methods. One hundred fifty-seven subjects with chronic lymphocytic leukemia in full or partial remission were enrolled in the study. Atorvastatin at doses 20 mg/d and 40 mg/d were prescribed for patients with hypercholesterinemia, dyslipidemia, coronary artery disease risk factors. All patients and control subjects underwent echocardiography, and 24-hour Holter monitoring with continuous time-dependent and spectral analysis of heart rate variability at baseline, after 1 year and after 3 years of observation period. Cardiovascular events were evaluated for 3 years observation period.
Results. In one year after reaching remission of CLL in comparing with baseline there is a statistical decrease in E (0.98 ± 0.15 м/с and 0.89 ± 0.16 м/с; P < 0.001), A (0.98 ± 0.16 м/с and 0.92 ± 0.15 м/с; p=0.023). E/A (P = 0.011) were significantly lower in group of patients without atorvastatin treatment (P = 0.011) and in group treated with atorvastatin in dose 20 mg a day (P = 0.002). In three year EF decreased in comparing with baseline (55.43 ± 4.75 % and 51.52 ± 6.40 % і; P = 0.009) in patients without atorvastatin treatment.
In three year global circular systolic strain (-17.42 ± 3.24% and -16.78 ± 3.56 %; P = 0.035), global longitudinal systolic strain (-18.13 ± 2.15 % and -17.04 ± 2.07 %; P = 0.008), global longitudinal systolic strain rate (-1.03 ± 0.23с-1 and -0.91 ± 0.33с-1; P = 0.024) were significantly decreased in patients without atorvastatin treatment. The LF values of group of patients treated without atorvastatin of patients were significantly lower than those of controls, and HF values of patients with CLL (P = 0.043) and HNL (P = 0.04) were lower.
Conclusions. Among patients with chronic lymphocytic leukemia in remission systolic and diastolic function, regional systolic contractility and variability of cardiac rhythm were significantly worse in three year especially in patients without atorvastatin treatment.
References
Kriachok, K. A. (2013) Khronicheskij limfolejkoz: novoe v lechenii. Podkhody k terapii pervoj linii i ikh e’volyuciya [Chronic lymphocytic leukemia: new in treatment Approaches to the first-line treatment and their evolution]. Klinicheskaya onkologiya, 3, 121–129. [in Russian].
Krasnov, L. A., & Olejnik, V. P. (2014) Monitorirovanie i analiz ritma serdca, Tekhnicheskie sredstva e'lektronnoj i komp'yuternoj diagnostiki v medicine [Monitoring and analysis of cardiac rhythm, technical methods of electronic and computer diagnostics in medicine: study manual]. Kharkiv. [in Russian].
Flakskampf, F. A. (Ed) (2013) Prakticheskaya e'khokardiografiya: Rukovodstvo po e'khokardiograficheskoj diagnostike [Practical electrocardiography: manual in echocardiographic dyagnostics]. Moscow. [in Russian].
Samura, B. B. (2015) Serdechno-sosudistye sobytiya i kachestvo zhizni u pacientov s khronicheskoj limphocitarnoj lejkemiej v remisii [Cardiovascular Events and Quality of Life in Patients with Chronic Lymphocytic Leukemia in Remission]. Medicina neotlozhnykh sostoyanij, 6(69), 36–43. [in Russian].
Tseluyko, V. I., & Radchenko, O. V. (2018) Serdechno-sosudistye zabolevaniya u onkologicheskikh bol’nykh [Cardiovascular disease in oncological patients]. Liky Ukrainy, 3, 7–20. [in Russian].
Armstrong, G. T., Oeffinger, K. C., Chen, Y., Kawashima, T., Yasui, Y., Leisenring, W., et al. (2013) Modifiable risk factors and major cardiac events among adult survivors of childhood cancer. J. Clin. Oncol., 31(29), 3673–3680. doi: 10.1200/JCO.2013.49.3205
Ewe, M. S., & Ewer, S. M. (2015) Cardiotoxicity of anticancer treatments. Nat Rev Cardiol., 12(11), 620. doi: 10.1038/nrcardio.2015.133.
Teo, K. K., & Burton, J. R. (2002) Who should receive HMG CoA reductase inhibitors? Drugs, 62(12), 1707–1715. doi: 10.2165/00003495-200262120-00001
Downloads
How to Cite
Issue
Section
License
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access)
